Frontlight ResearchEarly access
WithdrawnNo phase
SmartWatch ECG Evaluation Trial I
Key facts
- Who runs it
- University of Oklahoma
- Where
- Oklahoma City, United StatesSee the site
- Trial code
- Status
- Withdrawn
- Started
- Dec 2023
- Ended
- 18 Apr 2024
- Type of study
- Interventional
- Treatments tested
- We propose to validate these smartwatch ECG functions to support FDA submissions
- Record updated
- 22 May 2024
- Why it stopped
- The manufacturer who was to provide the study devices decided not to do so.
Who can take part
- Age
- 18 years to 90 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Male or female > 18 years of age
- Ability to understand and sign a written informed consent form, which must be obtained prior to initiation of any study procedures
- Being seen in the OU Cardiac Electrophysiology Outpatient Clinic
Who cannot take part
- Other conditions that in the opinion of the Lead Investigator may increase risk to the subject and/or compromise the quality of the clinical trial
- Inability or refusal of the patient and/or the patient's legally acceptable representative to provide written informed consent for any reason
Where in United States
- University of Oklahoma Health Sciences CenterOklahoma City, United States
About the trial
What the trial wants to find out
This is a single-center, non-randomized study to collect validation data for submission to the Food and Drug Administration (FDA) to support a 510(k) device clearance for a smartwatch ECG.
The group in the trial
- Screen groupTreatment being tested
This is a single-center, non-randomized open study with a single-patient clinical trial design (i.e., the patients serve as their own control).
Treatment: We propose to validate these smartwatch ECG functions to support FDA submissions
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 22 May 2024